Skip to main content
Premium Trial:

Request an Annual Quote

Epigenomics Inks Distribution Deal with Pronto for Colorectal Cancer Test

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Epigenomics and Pronto Diagnostics today announced a distribution agreement for Epigenomics' Epi proColon colorectal cancer test in Israel.

Pronto, based in Tel Aviv, Israel plans to begin marketing the test in Israel next month.

The test is based on Epigenomics' proprietary biomarker, Septin9, and is CE marked for sale in Germany, Austria, Switzerland. In a statement, Epigenomics, based in Berlin, said that the Epi proColon test is the firm CE-marked molecular diagnostic test for the early detection of colorectal cancer in blood.

The company said it plans to make the test broadly available, outside its home market through a mixture of direct commercialization and a distributor network.

Terms of the deal were not disclosed.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.